Human Vaccine Adjuvants Market Analysis, Size, and Share by 2030

The human vaccine adjuvants market value is projected to grow from US$ 1,571.41 million in 2022 to US$ 4,489.23 million by 2030. The human vaccine adjuvants market is further anticipated to record a CAGR of 14.0% from 2022 to 2030.

Increasing demand for personalized vacccines to improve vaccination efficacy and safety, leading to increased interest in personalized vaccines for treating diseases such as cancer, infectious diseases, and autoimmune disorders are likely to remain key trends in the market.

Human Vaccine Adjuvants Market Analysis

Human Vaccine adjuvants market is driven by the growing focus on immunization globally followed by the increasing burden of chronic diseases has led to a growing demand for vaccines that can prevent or manage these conditions. HIV, Hepatitis A, B, C, and HPV are some of the common communicable diseases which cen be prevented with the help of vaccinations. However, growing pharmaceutical industry is expected to develop new adjuvants along with vaccines which is likely to create ample opportunities in the coming years. Furthermore, rising trend of personalized vaccines has increased the collaboration among research institutes and increased the R&D activities which is expected to amplfy the market growth during forecast period.

Human Vaccine Adjuvants Market Overview

Human Vaccine adjuvants market is driven by the growing focus on immunization globally followed by the increasing burden of chronic diseases has led to a growing demand for vaccines that can prevent or manage these conditions. HIV, Hepatitis A, B, C, and HPV are some of the common communicable disease which cen be prevented with the help of vaccinations. Additionally, North America accounts for the major market share in 2022 owing to the increasing incidence of infectious diseases, increasing healthcare expenditure, and the presence of major market players. Asia Pacific is anticipated to grow with the highest CAGR in the coming years owing to the high prevalence of infectious diseases and initiatives by the government to provide free vaccinations through immunization programs in Asia Pacific countries.

Human Vaccine Adjuvants Market: Strategic Insights

Human Vaccine Adjuvants Market Drivers and Opportunities

Growing focus on Immunization to Favor Market

Governments of various nations recognize the importance of vaccination as a cost-effective strategy to prevent and control chronic diseases. According to the WHO, immunization currently prevents 3.5–5 million deaths yearly from diseases such as diphtheria, tetanus, pertussis, influenza, and measles. As a result, governments in various nations are implementing immunization programs to reduce the incidence of diseases such as cancer, diabetes, cardiovascular diseases, and respiratory diseases. These programs often target specific populations, such as children, older people, and high-risk individuals, to ensure they are adequately protected against these chronic conditions. The US, India, and Australia are among the key prominent nations that have effective immunization programs. For example, the US has the Vaccines for Children (VFC) program, which became operational in 1994 and is funded by the federal government. Similarly, India has the Universal Immunization Programme (UIP), which targets immunization of 26.7 million newborns and 29 million pregnant women annually. The United Nations International Children's Emergency Fund (UNICEF) also offers an immunization program that provides vaccines to protect children from life-threatening diseases globally.

Growing Pharmaceutical Industry Create Lucrative Growth Opportunities

The US has one of the most R&D-intensive pharmaceutical industries globally. According to the European Federation of Pharmaceutical Industries and Associations (EFPIA), the North America market (US and Canada) remained the world's largest market with a 49.1% share, well ahead of Europe, China, and Japan. The US is the global leader in innovative R&D investments, and the country produced over half of the world's new molecules in the last decade. Additionally, as per EFPIA, in 2021, North America accounted for 49.1% of global pharmaceutical sales, compared with 23.4% for Europe.

Similarly, according to the EFPIA, the Brazilian, Chinese, and Indian pharmaceutical industries grew by 11.7%, 6.7%, and 11.8% during the 2016–2021 period, respectively, compared to the top five European Union markets and the US market, which recorded an average market growth of 5.8% and 5.6%, respectively. Furthermore, as per the India Brand Equity Foundation (IBEF), India is a major and rising global pharmaceutical industry player. The country is the world's largest trader of generic medications, accounting for nearly 20% of the worldwide supply by volume. It supplies ~50% of the global vaccination demand. The domestic pharmaceutical industry includes a network of 3,000 drug companies and ~10,500 manufacturing units. Based on official figures from the Indian government, the pharmaceutical sector in India is valued at nearly US$ 50 billion, of which over US$ 25 billion is derived from exports. India accounts for ~20% of the world's generic medicine exports. As the industry continues to evolve and innovate, there is an increasing demand for adjuvants that can support the development of personalized vaccines, driving significant growth and investment in the human vaccine adjuvants market. Thus, the growing pharmaceutical industry worldwide will likely create lucrative growth opportunities for the human vaccine adjuvants market in the coming years.

Human Vaccine Adjuvants Market Report Segmentation Analysis

Key segments that contributed to the derivation of the Human vaccine adjuvants market analysis are type, application, and end user.

• Based on type, the Human vaccine adjuvants market is segmented into emulsion adjuvants, particulate adjuvants, combination adjuvants, and others. The particulate adjuvants segment held a largest market share in 2022.
• By application, the market is segmented into influenza, hepatitis, human papillomavirus (HPV), and others. The influenza segment held the largest share of the market in 2022.
• In terms of end user, the market is classified into pharmaceutical and biotechnology companies, CMOs and CROs, and others. The pharmaceutical and biotechnology companies segment held a largest share of the market in 2022.

Human Vaccine Adjuvants Market Share Analysis by Geography

The geographic scope of the Human vaccine adjuvants market report is mainly divided into five regions: North America, Asia Pacific, Europe, Middle East & Africa, and South & Central America.

North America has dominated the market and the US held the largest share of the market in 2022. The market in the country is projected to grow significantly during the forecast period owing to factors such as an increase in the incidence of infectious diseases, increasing healthcare expenditure, and the presence of major market players. According to the US Centers for Medicare & Medicaid Services, national healthcare expenditures in the US increased by 2.7% in 2021, reaching US$ 4.3 trillion or US$ 12,914 per person. Health spending accounted for 18.3% of the nation's GDP. As per the US Department of Health & Human Services, national health spending is expected to grow at an annual rate of 5.4% from 2019–2028, reaching US$ 6.2 trillion by 2028. The rising health expenditure may lead to a rise in funds allocation for the research and development of vaccines, fueling the demand for human vaccine adjuvants. Asia Pacific is anticipated to grow with the highest CAGR in the coming years owing to the high prevalence of infectious diseases and initiatives by the government to provide free vaccinations through immunization programs in Asia Pacific countries.

Human Vaccine Adjuvants Market Regional Insights

The regional trends and factors influencing the Human Vaccine Adjuvants Market throughout the forecast period have been thoroughly explained by the analysts at The Insight Partners. This section also discusses Human Vaccine Adjuvants Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.

Human Vaccine Adjuvants Market Report Scope

Human Vaccine Adjuvants Market Players Density: Understanding Its Impact on Business Dynamics

The Human Vaccine Adjuvants Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

Human Vaccine Adjuvants Market News and Recent Developments

The Human vaccine adjuvants market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the developments in the Human vaccine adjuvants market are listed below:

• SPI Pharma Inc collaborated with Q-Vant Biosciences Inc this partnership combines Q-Vant's technology with SPI global reach and services. The arrangement includes investment in the expansion of Q-Vant’s proprietary 100% sustainable Q-SAP technology and an exclusive commercial agreement to accelerate the global adoption of their saponin adjuvants for veterinary and human vaccine formulations. (Source: SPI Pharma, Newsletter, October 2023)
• Croda International Plc partnered with Amyris and Botanical Solutions Inc (BSI) for for the supply of biotechnology-derived, pharmaceutical grade squalene used in adjuvants to boost immune responses and to produce a sustainable pharmaceutical grade QS-21 vaccine adjuvant which enable the production of next generation adjuvant systems for new vaccine development respectively. (Source: Croda International Plc, Newsletter, May 2023)
• The Defense Threat Reduction Agency's (DTRA) Joint Science and Technology Office (JSTO) for the Chemical and Biological Defense (CBD) Program has awarded, through the Medical CBRN [Chemical, Biological, Radiological, and Nuclear] Defense Consortium (MCDC) requirement 22-05, "Adjuvant Activity to Vaccines Prototype," a 5-year contract totaling up to $31 million including program options to the team of Ginkgo Bioworks, Inc. and SaponiQx, Inc. to discover and develop next-generation vaccine adjuvants. This will require to use a combination of high-throughput empirical and artificial intelligence/machine learning approaches, including Generative Molecular Design (GMD), to develop superior novel saponin-based adjuvants.( Ginkgo Bioworks, Inc., Press Release, February 2024)

Human Vaccine Adjuvants Market Report Coverage and Deliverables

The “Human Vaccine Adjuvants Market Size and Forecast (2020–2030)” report provides a detailed analysis of the market covering below areas:

• Human vaccine adjuvants market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
• Human vaccine adjuvants market trends as well as market dynamics such as drivers, restraints, and key opportunities
• Detailed PEST/Porter’s Five Forces and SWOT analysis
• Human vaccine adjuvants market analysis covering key market trends, global and regional framework, major players, regulations, and recent market developments
• Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments for the Human vaccine adjuvants market
• Detailed company profiles